NVO Oct 2023 145.000 call
| Previous close | 17.30 |
| Open | 17.30 |
| Bid | 19.60 |
| Ask | 20.90 |
| Strike | 145.00 |
| Expiry date | 2023-10-20 |
| Day's range | 17.30 - 17.30 |
| Contract range | N/A |
| Volume | |
| Open interest | 27 |
ZacksNovartis Announces Positive Data on Breast Cancer Drug Kisqali
Novartis' (NVS) Kisqali reduces the risk of recurrence by 25% among patients with early breast cancer.
ZacksOncorus (ONCR) Dips 37% on Layoff Plan & Bankruptcy Threat
Oncorus (ONCR) decides to lay off nearly all of its workforce since it is facing challenges in raising additional capital. This lay off is expected to be completed by August 2023.
ZacksNovo Nordisk (NVO) Gears Up to Acquire BIOCORP for 154M Euros
Novo Nordisk (NVO) enters into negotiations to acquire a majority stake in BIOCORP, followed by a tender offer to acquire all remaining shares in BIOCORP for a total equity value of 154 million Euros.
ZacksAstraZeneca (AZN) Anticoagulant Drug Study Meets Efficacy Goal
At the interim analysis, AstraZeneca's (AZN) drug Andexxa showed superior hemostatic efficacy or in other words improved control of bleeding with targeted anticoagulation reversal versus usual care.
ZacksBest Momentum Stocks to Buy for June 5th
VIPS, KOF and NVO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 5, 2023.
ZacksIs Novo Nordisk (NVO) Stock Outpacing Its Medical Peers This Year?
Here is how Novo Nordisk (NVO) and Roche Holding AG (RHHBY) have performed compared to their sector so far this year.
Motley FoolNovo Nordisk's Smash-Hit Drug Could Become Even More Profitable. Here's Why.
Novo Nordisk's (NYSE: NVO) semaglutide is everywhere in the news, and for good reason. Thanks to its ability to help people lose weight and control their diabetes symptoms, its moneymaking potential is practically off the charts. At the moment, semaglutide is indicated to treat obesity and type 2 diabetes, and it's available in a few different formulations, which vary depending on the dosage and whether it's administered via a weekly injection or a once-per-day pill.
- Zacks
New Strong Buy Stocks for June 5th
NEM, KMT, VIPS, NVO and BAMXF have been added to the Zacks Rank #1 (Strong Buy) List on June 5, 2023.
Motley FoolCould Pfizer Have an Ozempic Killer on the Way?
It wasn't because so many patients were newly diagnosed with type 2 diabetes. Instead, Ozempic gained widespread popularity for helping people lose weight. A sibling product, Wegovy, a higher-dose version of the active ingredient in Ozempic that is actually approved for weight loss, has flown off pharmacies' shelves as well.
ReutersNovo Nordisk in talks buy controlling stake in Biocorp
The Danish company said it had entered into exclusive negotiations with Bio Jag, Biocorp's main shareholder, for the purchase of its over 45% stake in the French company at a price of 35.0 euros ($37.44) per share in cash. The price represents a premium of 19.5% over Biocorp's closing market price on June 2 and the transaction values Biocorp at about 154 million euros, the companies said. Certain minority shareholders, representing 19.0% of the share capital of Biocorp, will also transfer shares to Novo Nordisk and the transaction will be followed by a squeeze-out procedure.
Globe NewswireNovo Nordisk enters exclusive negotiations to acquire a controlling stake in BIOCORP, to be followed by a tender offer on all remaining shares
Novo Nordisk has entered into exclusive negotiations with BIO JAG, BIOCORP’s main shareholder, for the purchase of its entire stake in BIOCORP, representing 45.3% of its share capital and 62.2% of its theoretical voting rights, at a price of 35.00 Euros per share. Certain minority shareholders, representing 19.0% of the share capital and 13.07% of the theoretical voting rights of BIOCORP, have committed to transfer shares to Novo Nordisk upon completion of the acquisition of BIO JAG’s stake.The
ZacksZacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis
Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis have been highlighted in this Industry Outlook article.
ZacksPfizer (PFE) Posts Upbeat Data From Hemophilia Drug Study
Data from a late-stage study shows that treatment with Pfizer's (PFE) experimental anti-TFPI inhibitor led to a significant reduction in annualized bleeding rate in hemophilia A and B patients.
Motley FoolGot $5,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond.
These stocks have moved in opposite directions lately, but both could deliver solid returns to patient investors.
Motley FoolDoes Pfizer Have a Weight-Loss Pill That's Better Than Ozempic?
A highly lucrative weight-loss market could be the growth opportunity Pfizer needs to make the stock a better buy.
Motley FoolThis Could Be Novo Nordisk's Next Big Weight-Loss Product
The company's sales doubled last quarter, prompting it to upgrade its guidance.
Zacks5 Large Drug Stocks to Watch From a Thriving Industry
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Roche (RHHBY) and Novartis (NVS) are worth retaining in your portfolio.
Motley FoolThe Best Stocks to Invest $5,000 in Right Now
Two that come to mind are Danish pharmaceutical company Novo Nordisk (NYSE: NVO) and U.S.-based integrated healthcare benefits company UnitedHealth Group (NYSE: UNH). The companies have their own tailwinds as well, with Novo Nordisk building revenue off its weight-loss franchise and UnitedHealth Group finding its foray into Medicare Advantage to be lucrative. Novo Nordisk's shares are up more than 19%.
ZacksBrokers Suggest Investing in Novo Nordisk (NVO): Read This Before Placing a Bet
The average brokerage recommendation (ABR) for Novo Nordisk (NVO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Motley FoolBetter Dividend Stock: Eli Lilly or Novo Nordisk?
Dividend stocks, on balance, tend to deliver market-beating returns on capital over the long haul. The key reason is that regular dividend payments amplify returns through the power of compounding. Selecting dividend stocks is no easy task, however.
- Globe Newswire
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 30 May 2023 – On 9 May 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under the programme initiate
Motley FoolThis Pharma's Sales Are So Hot It's Trying to Curb Demand
Novo Nordisk (NYSE: NVO) is planning to pause some of its advertising campaigns for its obesity drug Wegovy, due to white-hot demand in the U.S. The impact of the move isn't the marketing costs it saves, but the unambiguous message it sends: Wegovy is probably going to bring in even more sales than management expected -- and it had expected quite a bit. This isn't the first time that demand for Wegovy has been greater than what the pharma can manufacture, and it's no surprise why.
- Zacks
Novo Nordisk (NVO) Growth Hormone Drug Gets Positive CHMP Opinion
Novo Nordisk (NVO) gets CHMP recommendation approval for Sogroya for expanded use in children and adolescents with growth hormone deficiency.
Yahoo Finance VideoPfizer weight loss drug may be as effective as competitors: Study
Yahoo Finance Live health care reporter Anjalee Khemlani details the clinical trial results of Pfizer's weight loss drug Danuglipron, how it compares to Novo Nordisk's Ozempic, and examines the adoption of weight loss drugs in the health and wellness space.
ZacksHere's Why Novo Nordisk (NVO) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
